Seborrheic Dermatitis Market Report 2024 - Size, Share, Trends, Outlook, Overview And Forecast To 2033

"The new report published by The Business Research Company, titled ""Seborrheic Dermatitis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the seborrheic dermatitis market size has grown rapidly in recent years. It will grow from $2.46 billion in 2023 to $2.76 billion in 2024 at a compound annual growth rate (CAGR) of 11.9%. The seborrheic dermatitis market size is expected to see rapid growth in the next few years. It will grow to $4.14 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13159&type=smp

Rising Prevalence Of Dermatological Diseases Fuels Seborrheic Dermatitis Market Growth
The increasing prevalence of dermatological diseases is expected to propel the growth of the seborrheic dermatitis market going forward. Dermatological diseases refer to various medical conditions affecting the skin, hair, nails, and mucous membranes. The treatment of dermatological diseases provides relief from discomfort, improves the appearance of the skin, and, in many cases, helps prevent complications such as infections or scarring, thereby enhancing the overall quality of life for affected individuals. For instance, in December 2022, according to the data from the National Psoriasis Foundation, a US-based non-profit organization, about 125 million people worldwide were affected by psoriasis (a type of dermatological disease), which is roughly 2-3% of the global population. Additionally, over 8 million Americans were reported to have psoriasis in 2022. Therefore, the increasing prevalence of dermatological diseases will drive the growth of the seborrheic dermatitis market.

Arcutis Biotherapeutics Introduces Innovative Roflumilast Foam For Seborrheic Dermatitis
Major companies operating in the seborrheic dermatitis market are focusing on developing novel and more effective medical therapies, such as roflumilast foam, to drive revenues in the market. Roflumilast foam is an innovative and improved daily-use topical treatment for inflammatory skin conditions, focusing on hair-bearing areas like the scalp, face, and trunk. For instance, in April 2023, Arcutis Biotherapeutics Inc., a US-based medical dermatology company, unveiled its new drug, roflumilast foam 0.3%, the first topical drug with a unique mechanism of action for seborrheic dermatitis in over two decades to be approved by the Food and Drug Administration (FDA), a US-based government agency. Roflumilast foam is an investigational, once-daily, topical formulation of a highly potent and selective phosphodiesterase type 4 (PDE4) inhibitor developed to treat inflammatory dermatoses, particularly in hair-bearing areas of the body. This drug is used to treat seborrheic dermatitis in individuals aged nine years and older.

The seborrheic dermatitis market covered in this report is segmented -

1) By Treatment: Anti-Inflammatory, Antifungal, Corticosteroid Lotions, Sulfur Products, Other Treatments
2) By Diagnosis: Physical Examination, Biopsy, Other Diagnoses
3) By Dosage Form: Creams, Shampoos, Ointments, Gels, Other Dosage Forms
4) By Route Of Administration: Oral, Topical, Parenteral, Other Route Of Administrations
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13159&type=discount

Major companies operating in the seborrheic dermatitis market report are Pfizer Inc., Johnson and Johnson, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Co, Abbott Laboratories, GlaxoSmithKline Plc, Acella Pharmaceuticals LLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Galderma S.A., Dr. Reddy's Laboratories Ltd., Cipla Limited, Getinge AB, Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Lupin Limited, Monarch Pharmachem, Alliance Pharma plc, Genentech Inc., Zydus Group, Arcutis Biotherapeutics Inc.

Contents of the report:
1. Executive Summary
2. Seborrheic Dermatitis Market Report Structure
3. Seborrheic Dermatitis Market Trends And Strategies
4. Seborrheic Dermatitis Market - Macro Economic Scenario
5. Seborrheic Dermatitis Market Size And Growth
…..
27. Seborrheic Dermatitis Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/seborrheic-dermatitis-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.